

SANDOSTATIN LAR - Administration video - HCP

[Prescribing information](#)

Image



Image



 **Sandostatin[®] LAR[®]**
octreotide / IM INJECTION

How to administer and prepare SANDOSTATIN[®] LAR[®] (octreotide acetate)



Mixing and Administration

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk_patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report. If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com.

VIDEO

UK | February 2025 | FA-11214504

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online

through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/oncology/sandostatin-lar/administration-video>